Transcript of Earnings call with Analyst/Investor on Financial Results for the fourth quarter and year ended March 31, 2026
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Corona Remedies reported strong FY26 results with revenue of INR 1,403 crores (up 17% YoY) and PAT of INR 199 crores (up 33% YoY), beating its guided 15% revenue and 20% PAT growth targets. The company declared 100% dividend (INR 10 per share). Q4 margins declined 90bps to 17.6% due to costs of launching two new divisions (multi-specialty and infertility), adding 450 medical representatives (MR strength now at 3,100). Full-year EBITDA margin improved 80bps to 20.9%. The company completed two acquisitions in FY26 - Wokadine (INR 20 crore brand, ranked #2 in Povidone Iodine market) and Bayer Zydus portfolio (7 brands in women's health/IVF). Three biosimilar products were launched including Semaglutide brands (Wyntide and Tyvenza). International business grew 29.5% but remains ~4% of revenue. Company guides for FY27: 15% organic revenue growth and 25% growth from acquired brands with 20%+ PAT growth.
The company demonstrated robust execution beating guidance, though Q4 margin weakness was a one-time cost from expansion. Management guides sustained 20%+ PAT growth for FY27, indicating confidence in operational leverage from new MR hires and acquired brands. Strong cash flows (CFO/EBITDA at 78%) and high ROCE of 41% support shareholder returns.